Eyenovia reacquires MicroPine rights from B&L for $2M cash + $3M stock

HYPERION DEFI, INC.

Reacquired U.S. and Canada rights to MicroPine (late-phase III pediatric progressive myopia) from Bausch + Lomb Ireland.
Consideration: $2M upfront cash + $3M in common stock + low single-digit royalty on net sales in U.S./Canada.
MicroPine uses Optejet dispenser; market estimated at ~$2B annually in the U.S. by Review of Myopia Management.
Ongoing CHAPERONE trial to be transferred; Eyenovia plans to meet with FDA to explore expedited development path.
No impact on partnership with Arctic Vision covering Greater China and South Korea.

item 1.01 item 1.02 item 3.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.92

HYPERION DEFI, INC. entered into Letter Agreement with Bausch + Lomb Ireland Limited valued at cash and common stock consideration; $2 million upfront cash payment; $3 million in common stock; lo (effective 2024-01-12).

Action: entry
Agreement: license
Counterparty: Bausch + Lomb Ireland Limited
Value: cash and common stock consideration; $2 million upfront cash payment; $3 million in common stock; lo
Effective: 2024-01-12

Exact text from the filing

On January 12, 2024, after successful negotiations between Eyenovia and B&L regarding the pediatric progressive myopia program, B&L and Eyenovia entered into a Letter Agreement (the “Letter Agreement”), pursuant to which Eyenovia will reacquire the rights to this program.

View on SEC.gov

Browse all material agreements →

HYPERION DEFI, INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-003908

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.